[Form 4] Halozyme Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Helen Torley, President and CEO and director of Halozyme Therapeutics (HALO), reported option exercises and share sales under a Rule 10b5-1 trading plan adopted March 21, 2025. She exercised multiple option blocks with an $8.11 exercise price on September 2-4, 2025, acquiring 60,000 shares from option exercises and receiving 60,000 option shares underlying those exercises. Concurrently she sold aggregated blocks of common stock on September 2-4, 2025 at weighted average prices reported in ranges between $71.99 and $75.44 per share. After these transactions, Ms. Torley beneficially owned 733,719 common shares and held remaining options exercisable into additional shares as reported.

Positive

• Transactions were executed under a Rule 10b5-1 written trading plan, reducing ambiguity about timing and intent
• Reporting person retained substantial ownership after transactions (733,719 shares beneficially owned as reported)
• Options exercised at a low strike price of $8.11, consistent with long-dated grants (grant date Feb. 3, 2016)

Negative

• Significant share sales occurred on September 2-4, 2025, with reported weighted price ranges between $71.99 and $75.44, reducing immediate holdings
• Beneficial ownership decreased from pre-sale levels as shown by multiple disposals across the reported dates

Insights

Corporate Governance Expert

TL;DR: Insider exercised long-dated options and sold shares under a documented 10b5-1 plan; transactions are routine and pre-planned.

These disclosures show the CEO and director used a Rule 10b5-1 plan to exercise options with an $8.11 strike and effect multiple sales in early September 2025. The plan and contemporaneous exercises reduce legal/insider-trading risk by documenting intent. The Form 4 shows meaningful retained ownership (over 700k shares) and remaining exercisable options; this pattern is consistent with liquidity actions rather than an unplanned disposition.

Securities Analyst

TL;DR: Option exercises and sales generated proceeds at prices in the low-mid $70 range; ownership remains substantial post-transactions.

The filing quantifies exercises of options granted February 3, 2016 (four-year vesting originally) at an $8.11 exercise price and recorded multiple sales with weighted average sale prices within $71.99–$75.44 per share. Following the reported transactions, the reporting person beneficially owned 733,719 shares and held remaining options exercisable into additional shares as disclosed. The activity was executed under a previously adopted 10b5-1 plan, limiting timing uncertainty.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Torley Helen

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	09/02/2025		S(1)		300	D	$72.485(2)	753,419	D
Common Stock	09/02/2025		S(1)		16,288	D	$73.698(3)	737,131	D
Common Stock	09/02/2025		S(1)		3,412	D	$74.147(4)	733,719	D
Common Stock	09/03/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	09/03/2025		S(1)		9,500	D	$74.22(5)	744,219	D
Common Stock	09/03/2025		S(1)		10,500	D	$74.632(6)	733,719	D
Common Stock	09/04/2025		M(1)		20,000	A	$8.11	753,719	D
Common Stock	09/04/2025		S(1)		9,900	D	$73.536(7)	743,819	D
Common Stock	09/04/2025		S(1)		7,800	D	$74.327(8)	736,019	D
Common Stock	09/04/2025		S(1)		2,300	D	$75.224(9)	733,719	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$8.11	09/02/2025		M(1)			20,000	(10)	02/03/2026	Common Stock	20,000	$8.11	176,569	D
Option to Purchase Common Stock	$8.11	09/03/2025		M(1)			20,000	(10)	02/03/2026	Common Stock	20,000	$8.11	156,569	D
Option to Purchase Common Stock	$8.11	09/04/2025		M(1)			20,000	(10)	02/03/2026	Common Stock	20,000	$8.11	136,569	D

Explanation of Responses:

1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026.

2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $71.99 to $72.81. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.03 to $74.02. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.03 to $74.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.48 to $74.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

6. Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.48 to $74.93. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

7. Represents a weighted average sales price per share. The shares were sold at prices ranging from $73.06 to $74.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

8. Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.06 to $74.96. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

9. Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.11 to $75.44. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

10. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016.

	/s/ James R. Oehler, Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HALO insider Helen Torley do according to the Form 4?

The Form 4 reports that Helen Torley exercised options at $8.11 and sold common shares on September 2-4, 2025 under a Rule 10b5-1 trading plan.

How many shares did the reporting person acquire by exercise and how many do they own after the transactions?

The reporting person exercised 60,000 option shares (three exercises of 20,000 each) and beneficially owned 733,719 common shares following the reported transactions.

At what prices were the shares sold in these transactions?

Sales occurred at weighted average prices with reported ranges from $71.99 to $75.44 per share, and specific weighted averages listed on the Form 4 for each block.

Were these transactions pre-planned or discretionary?

The Form 4 states the option exercises and sales were made pursuant to a written trading plan adopted March 21, 2025 in accordance with Rule 10b5-1.

What is the exercise price and original grant information for the options exercised?

The options exercised had an $8.11 exercise price and relate to options granted on February 3, 2016 with a four-year vesting schedule as described on the Form 4.